MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a

Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study

(2016) Giancarlo Comi et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Assessing response to interferon-β in a multicenter dataset of patients with MS

(2016) Maria Pia Sormani et al.   NEUROLOGY

Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15

(2015) Ludwig Kappos et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

(2015) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

Scoring treatment response in patients with relapsing multiple sclerosis

(2012) MP Sormani et al.   Multiple Sclerosis Journal

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

(2011) Giancarlo Comi et al.   LANCET NEUROLOGY

Measures in the first year of therapy predict the response to interferon β in MS

(2009) J Río et al.   Multiple Sclerosis Journal